CHA Vaccine Research Institute

A261780

The current CHA Vaccine Research Institute (A261780) market capitalization is approximately ₩72.80B, based on its latest share price and shares outstanding. Market capitalization represents the total market value of a company's equity and is calculated by multiplying the current stock price by the number of shares outstanding. As a result, CHA Vaccine Research Institute's market cap fluctuates with changes in its share price and share count. Last updated: March 7, 2026 at 8:28 PM Eastern Time

In the most recently reported quarter, CHA Vaccine Research Institute (A261780) generated ₩158.62M in revenue. Quarterly revenue results and expectations reflect underlying demand trends, pricing dynamics, product or service mix, seasonality, and broader macroeconomic conditions. Actual results may differ from consensus estimates as new information becomes available. Last updated: April 2, 2026 at 2:44 AM Eastern Time

In the most recently reported fiscal year, CHA Vaccine Research Institute (A261780) generated net income of ₩-16.04B, compared with ₩-10.14B in the prior fiscal year, representing a -58.26% year over year change. Net income may be positive or negative and can fluctuate materially from year to year due to changes in operating performance, non-recurring or one-time items, accounting treatments, capital structure, and broader macroeconomic conditions. Last updated: April 2, 2026 at 2:44 AM Eastern Time

According to its latest quarterly filing, CHA Vaccine Research Institute (A261780) reported EBITDA of ₩-2.96B, representing a -53.94% year over year change. EBITDA is a non-GAAP measure and does not account for depreciation, amortization, interest expense, taxes, or capital expenditures. As a result, it should be considered alongside other financial metrics when assessing operating performance. Actual results may differ from estimates as company-specific or macroeconomic conditions evolve. Last updated: April 2, 2026 at 2:44 AM Eastern Time

As of the most recent reporting period, the company's debt-to-equity ratio stands at 0.50x, calculated as total debt divided by total shareholders' equity. A lower debt-to-equity ratio generally indicates a more conservative capital structure with less reliance on external borrowing, while a higher ratio suggests greater financial leverage and potentially higher sensitivity to interest rates, refinancing conditions, and earnings volatility. The debt-to-equity ratio should be interpreted in the context of the company's industry, business model, cash flow stability, and balance sheet composition. Last updated: April 2, 2026 at 2:44 AM Eastern Time

Based on the latest available data, CHA Vaccine Research Institute (A261780) is currently trading at a last twelve months (LTM) P/E ratio of -5.88x. The P/E ratio reflects how much investors are willing to pay today for a dollar of earnings and can vary meaningfully over time due to changes in profitability, growth expectations, margin outlook, and earnings volatility. Last updated: April 2, 2026 at 2:44 AM Eastern Time

In the most recently reported quarter, CHA Vaccine Research Institute (A261780) revenue was ₩158.62M. Earnings per share (EPS) for the quarter were ₩-0.14K. Revenue and EPS surprises may be positive or negative and can influence near-term stock performance depending on expectations, forward guidance, and broader market and sector conditions. For a detailed history of analyst expectations versus reported results, view the full estimates vs. actuals track record here: 👉 Estimates vs. Actuals Last updated: April 2, 2026 at 2:44 AM Eastern Time

CHA Vaccine Research Institute (A261780) does not currently pay a dividend. Over the last twelve months (LTM), the company paid ₩0.00 per share in dividends, and no dividend payments are currently expected over the next twelve months (NTM). Companies that do not pay dividends typically prioritize reinvesting cash into growth initiatives, capital expenditures, debt reduction, or strategic investments, though dividend policy may change in the future. Last updated: April 2, 2026 at 2:44 AM Eastern Time

Based on the latest available analyst coverage, CHA Vaccine Research Institute (A261780) currently carries a not available consensus rating. Analyst views are forward-looking estimates and should not be considered investment advice. Last updated: April 2, 2026 at 2:44 AM Eastern Time

Like other publicly traded stocks, CHA Vaccine Research Institute (A261780) shares are bought and sold on stock exchanges such as KOSDAQ and other supported markets, depending on the listing. The most common way to buy shares is through an online brokerage account. To get started, you typically need to: Open an account with a licensed stock brokerComplete the broker's verification processFund your accountPlace a buy order for CHA Vaccine Research Institute (A261780) shares Trading involves risk, and investors should consider their financial objectives and risk tolerance before investing.

At the top right of this page, you'll see a star icon labeled Add to watchlist. Click it to add A261780 to your watchlist.

CHA Vaccine Research Institute trades under the ticker symbol A261780 on the KOSDAQ stock exchange. The ticker A261780 is used to identify the company's common stock across trading platforms, market data providers, and regulatory filings.

CHA Vaccine Research Institute (A261780) operates in a highly competitive market with companies that often have different business models, geographic exposure, and end markets. While no two companies are identical, the following firms are generally considered the closest CHA Vaccine Research Institute (A261780) stock peers based on overlapping products, services, and competitive dynamics:Serina Therapeutics (SER) (A153710)Inovio Pharmaceuticals (INO)SK bioscience (A302440)Paradigm Biopharmaceuticals (PAR)GeneOne Life Science (A011000)Noxopharm (NOX)EyeGene (A185490)Imugene (IMU)SillaJen (A215600) These peers may differ in size, business mix, financial profile, and strategic focus, but they are commonly referenced due to overlapping markets, customer segments, or competitive positioning relative to CHA Vaccine Research Institute.